Novel drug prevents common viral disease in stem-cell transplant patients, study finds

by Rob Levy

A new drug can often prevent a common, sometimes severe viral disease in patients receiving a transplant of donated blood-making stem cells, a clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital indicates.

In a paper in the Sept. 26 issue of the New England Journal of Medicine, the researchers report that patients who took the drug CMX001 shortly after transplant were far less likely to develop cytomegalovirus (CMV) infection than were patients who took a placebo. CMV disease is a common source of illness in transplant patients and can cause pneumonia, diarrhea and digestive tract ulcers, or other problems. Although some , when administered at the earliest signs of CMV infection, often forestall CMV disease, they often cause or impair patients' ability to make new .

"With current agents, between 3 and 5 percent of allogeneic [donor] transplant patients develop CMV disease within six months of transplantation, and a small number of them may die of it," says study lead author Francisco Marty, MD, of Dana-Farber and Brigham and Women's. "There clearly is a need for better treatments with fewer adverse effects. This clinical trial examined whether the disease can be prevented, rather than waiting for blood tests to show that treatment is needed."

CMV is a herpes-like virus that infects the majority of Americans by adulthood. Most often, it is held in check by the immune system and produces no symptoms. Most people are unaware they are infected, Marty explains.

In stem-cell transplant patients, however, the immune system – based in the blood-making tissue of the bone marrow – is replaced with -making cells after patients receive high doses of chemotherapy. During this transition period, long-dormant viruses like CMV may have an opportunity to become active. The result can be CMV disease.

The new, phase II clinical trial involved 230 hematopoietic (blood-making) recipients at 27 treatment centers across the United States. They participants were randomly assigned to receive either oral CMX001 (at varying doses) or a placebo, which they began taking after the transplanted cells engrafted, or took root in the bone marrow – which usually occurs two to three weeks after the transplant procedure. They took the pills for 9-11 weeks.

Only 10 percent of the patients who took 100 mg of CMX001 twice a week had a "CMV event" – defined as CMV disease that affects the lung, digestive tract, or other organs, or a detectable amount of CMV in the blood at the end of treatment – the investigators found. By contrast, CMV events occurred in 37 percent of those who received a placebo. The most common adverse side effect to CMX001 was diarrhea.

"The results show the effectiveness of CMX001 in preventing CMV infections in this group of patients," Marty says. "Because CMX001 is known to be active against other herpes viruses and against adenoviruses that sometimes affect transplant patients, it may be useful as a preventive or treatment agent for those infections as well."

Related Stories

How a virus might make you diabetic later in life

Aug 27, 2012

Cytomegalovirus (CMV) is one of the viruses that most infected people carry without ill effects. Once infected you are infected for life and, although it normally is dormant, it can become active again at any point in time. ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments